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  II 
Abstract 
 
 
Objectives: 1) To review costs of prostate cancer care in multiple countries 2) To summarize 
studies assessing regional variation in costs of prostate cancer care within the United States 3) To 
characterize variation across hospital referral regions (HRRs) in Medicare expenditures on initial 
prostate cancer care and evaluate its determinants. Methods: A thorough literature search was 
conducted to identify the costs of prostate cancer care in different countries and within the 
United States (to assess regional variation in costs). Subsequently, the thesis involved an in-
depth use of the Surveillance, Epidemiology and End Results (SEER)-Medicare linked database 
and the Medicare 5% random sample of non-cancer beneficiaries in the SEER-17 regions. Each 
man identified with first primary localized prostate cancer was matched to a man without cancer 
based on age, race, comorbidity and date of diagnosis. We estimated Medicare expenditure on 
prostate cancer-related care by calculating the incremental expenditure between cancer patients 
and the controls during the initial phase of care. Hierarchical generalized linear models were 
used for risk adjustment. Results: Total Medicare expenditure on prostate cancer-related care 
averaged $15,567 per patient. HRRs in the highest quintile had an average expenditure of 
$19,236 per patient, which was $6,664 (or 53%) higher than HRRs in the lowest quintile (i.e., 
$12,572). There was also large variation in radiation therapy costs, with average expenditures 
ranging from $7,948 to $13,522 in the lowest and highest spending quintiles, respectively. 
Patient demographic, clinical, and treatment factors explained 19% of the variation in total 
cancer-related expenditure across the HRR quintiles. Conclusions: There are few cost studies 
that study geographic variation in costs of prostate cancer care. They conclude that there is 
variation in costs of prostate cancer care between countries. The analysis conducted for the 
United States shows substantial regional variation in Medicare expenditures on initial prostate 
cancer care. Patient demographic and clinical characteristics did not explain this variation, while 
the use of active treatment versus watchful waiting and the utilization of specific treatment 
strategies explained a relatively small percentage of the variation. 
Keywords: prostate cancer, regional variation, hospital referral region, cost 
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Chapter 1: Introduction 
1.1 Global Burden of Cancer 
Cancer is a chronic disease associated with high morbidity and mortality worldwide.  It is 
projected that there would be a 70% increase in annual cancer incidence by 2030 owing to 
demographic changes; wherein the largest increases would be in the lower-income countries. [1] 
According to estimates from the GLOBOCAN series by the International Agency for Research 
on Cancer (IARC), there were 12.7 million new cancer cases in 2008 worldwide, of which 5.6 
million were in developed countries and 7.1 million in developing countries.[2] A rapid increase 
in the prevalence of cancer in the low and middle-income countries has led to massive loss of 
productivity and life-years causing the “largest drain on global economy” compared to other 
causes of death like Human Immunodeficiency Virus (HIV) and other infectious disease.[3] 
Focus on cancer prevention and control in the developed countries is definitely a priority but the 
picture projected for the developing countries categorizes cancer as a “silent pandemic”.[3] With 
increasing globalization and adoption of western life styles, many factors such as unhealthy diet, 
lack of exercise, tobacco, alcohol consumption, and environmental hazards due to 
industrialization have resulted in a disease mix in low and middle-income countries that is 
similar to that in high-income countries.[4]  
As for mortality, an estimated 7.6 million of deaths worldwide could be attributed to 
cancer in 2008, which accounts for approximately 21% of all deaths due to non-communicable 
diseases.[1] It is certainly important to continue and strengthen our effort to battle malaria, 
tuberculosis, HIV and many other infectious diseases, but we also need to be vigilant about the 
serious threat posed by cancer to the global health systems. 
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1.2 Economic Burden of Cancer 
Because of its high morbidity and mortality, cancer represents a substantial economic 
burden.  The cost of cancer care can be divided into three components: direct medical costs; 
extra financial requirement of living with disease for the patient and their family; and loss of 
income from premature death.[5] The American Cancer Society estimated that the total 
economic impact of premature death and disability caused by cancer was $895 billion worldwide 
in 2008, and this figure excluded direct medical costs.[6] In addition, approximately 83 million 
“healthy years” were lost due to cancer-related death and disability.[6] The direct medical costs 
would encompass the costs of cancer diagnosis and treatment.  From a societal perspective and in 
order to allocate “limited” resources appropriately, we need to assess the cost of each and every 
health service utilized to treat a disease.[7] Such studies of between and within countries, 
differences in costs for disease groups or specific diseases will be helpful to manage and design 
health interventions and policies with respect to evidence based practice, prevention, screening, 
clinical management and resource allocation. 
1.3 Prostate Cancer 
Of all types of cancer, I am particularly interested in prostate cancer because it high 
incidence and unique regional variation in incidence due to health system factors (e.g., screening 
and diagnostic patterns).  Globally, prostate cancer is the second most common cancer in men 
and fifth most common cancer overall with almost 914,000 new incident cases (13.8% of total 
cancer).[2] There is a substantial geographic variation in the incidence of prostate cancer  - 
almost 75% percent of the registered cases occur in developed regions like Australia, New 
Zealand, United States and Europe, which is likely due to the widespread use of prostate specific 
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antigen (PSA) screening tests as well as biopsy in these regions.[2] Not surprisingly, prostate 
cancer incidence is positively correlated with Human Development Index, and the higher 
incidence can be attributed to better access to diagnostic resources.[8] In the United States, for 
example, prostate cancer is the most common type of cancer in men, and the life-time risk for a 
man to be diagnosed with prostate cancer was more than 16% in 2009.[9] 
Even in developing countries where screening is uncommon and diagnostic resources 
tend to be limited, prostate cancer is also a looming threat.  For instance, prostate cancer is one 
of the most common cancers and cause of cancer death in Sub-Saharan African countries.[8] 
Mortality rates of prostate cancer show a 10-fold difference between regions, in contrast to the 
25-fold regional difference in incidence.[2] The number of deaths from prostate cancer in the 
developed and developing world was 136,000 and 122,000 in 2008, respectively.[2] 
1.4 Costs of Prostate Cancer Care 
The management of prostate cancer remains complex depending on the stage at which it 
is detected, age of the patient, presence of co-morbidities and treatment norms and strategies 
employed in a particular health system.[10] The most common treatment strategies include 
watchful waiting (WW), surgery, radiation therapy and hormonal therapy, and current debate 
revolves around lack of clarity regarding the best treatment strategy and the costs attributed to 
the specific treatment.[10] Irrespective of the treatment employed, the clinical and economic 
implications of prostate cancer were large.[10] In order to rein in healthcare costs, we need to 
understand how the treatments and costs vary by country and regionally within a country.    
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1.5 Aims of this Thesis 
 
In this thesis, I aim to: 
1. To review costs of prostate cancer care in multiple countries (Chapter 2) 
2. To summarize studies assessing regional variation in costs of prostate cancer care 
within the United States (Chapter 2) 
3. To evaluate regional variation in costs of prostate cancer care within the U.S 
using 2003-2007 Surveillance, Epidemiology, and End Results (SEER)-Medicare 
data (Chapter 3) 
To accomplish these aims, I first conducted a thorough literature search, which included 
two major areas: (1) the costs of prostate cancer care in different countries in order to evaluate 
potential global variation; and (2) the costs of prostate cancer care within the United States to 
assess regional variation in costs and its relation to treatments.  The last part of the thesis 
involves an in-depth analysis to assess the types of treatment and the related direct medical costs 
for a large, population-based cohort of elderly prostate cancer patients diagnosed in the United 
States during 2003-2007.  Together, I hope this thesis will shed light on the costs of prostate 
cancer care and issues surrounding its surge within the United States and globally. 
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Chapter 2: Global Variation in the Costs of Prostate Cancer Care 
 
2.1 Global Burden of Prostate Cancer 
Globally, prostate cancer is the second most common cancer in men and fifth most 
common cancer overall with almost 914,000 new incident cases.[2] An average 3% of increase 
in annual prostate cancer incidence is projected in all regions around the world, irrespective of 
the human development index.[8] Prostate cancer used to be diagnosed primarily in the high-
income nations, but there has been a gradual rise in the incidence in the developing 
countries.[11]   
The rank of prostate cancer as a cause of death is going up in many regions such as Asia 
Pacific, Caribbean, and Latin America, where prostate cancer was not a major concern in the 
past.[12] In the high-income regions such as North America, Australasia, Western Europe where 
prostate cancer has been prevalent, the rank has not shown any improvement (Table 1).[12] It 
appears that the burden of prostate cancer is increasing in developing countries, while remaining 
relatively stable in developed countries.  Directly comparing the data between/across the 
countries may not be appropriate, as they depend each individual country’s infrastructure for 
maintaining cancer registries, screening and diagnosing prostate cancer.[11]    
The mortality rate due to prostate cancer went up during the last two decades  
(5.83/100,000 person-years in 1990 and 7.37/100,000 person-years in 2010) (Figure 1),[13] and 
the years of life lost due to disability (YLD) has almost doubled during the same time period (6.2 
per 100,000 in 1990 and 13.42 per 100,000 in 2010 (Figure 2).[13]  
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2.2 Costs of Prostate Cancer 
In order to allocate healthcare resources appropriately, it is important to assess the costs 
of prostate cancer.  Differences in cancer costs across various countries can be attributed to the 
differences in incidence, prevalence, mortality, and patterns of care.[14] Broadly, the costs of 
cancer in a society can be divided into direct costs (i.e., screening, diagnosis and treatment) and 
indirect costs (e.g., loss of productive time and disability).[14] Since it is challenging to tease out 
the costs attributed to prostate cancer from the total costs due to all the diseases/health conditions 
an individual might have (i.e., prostate cancer and comorbidities), the focus of this review will be 
to assess the direct costs of prostate cancer care. 
There has long been debate on how best to treat patients with prostate cancer.  No single 
treatment strategy is guaranteed to lead to better outcomes, but the choice of treatment definitely 
affects the total costs of care.[15] Treatment options for localized prostate cancer include 
watchful waiting, radical prostatectomy, radiation therapy and hormonal therapy.  Some newer 
therapeutic protocols such as robot-assisted radical prostatectomy (RARP) and intensity-
modulated radiotherapy (IMRT) have been rapidly adopted into clinical practice on a large scale, 
without rigorous assessments of their cost-effectiveness.[15] This has led to increase in costs of 
prostate cancer treatment with unclear impact on outcomes. High quality studies comparing the 
total costs of screening, diagnosis and treatment for prostate cancer across different countries are 
needed to inform health policy and healthcare service delivery. Unfortunately, such studies are 
scant.   
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2.2 a Costs of Screening, Diagnosis and Staging 
The efficacy of screening for prostate cancer using prostate-specific antigen (PSA) 
testing is questionable.[16] If screening is effective, we would expect fewer advanced cases, 
which has not been the case.[16] Multiple randomized trials suggest that PSA-based screening 
does not reduce prostate cancer mortality.[17] 
Ekwueme et al. recently reviewed the resource costs of screening, diagnosis and staging 
in the United States and other industrialized nations such as Canada, Sweden, the United 
Kingdom, Australia and Japan.[17] The resource costs included direct costs such as physician 
consultation, supplies, and effort of medical staff, as well as indirect costs such as travel time, 
loss of income, and transportation cost.[17] Interestingly, the mean costs of screening were 
relatively similar across different countries, but the costs of diagnosis and staging varied 
substantially (Table 2).[17] 
 PSA-based prostate cancer screening became popular in the 1990s due to the results from 
the European Study of Screening of Prostate Cancer (ERSPC) that demonstrated a 20% decrease 
in prostate cancer mortality.[18] However, a subsequent evaluation study critiqued that 
suggesting that PSA screening would be cost effective only when the lifelong treatment costs are 
below $1,868 per life-year.[18] Therefore, in addition to inventing cost-effective screening 
technologies, we should aim to reduce treatment costs since much of the controversy surrounding 
the use of screening has been due to the lack of cost-effective early treatment strategies for 
prostate cancer.[19] 
 
 
 
  8 
2.2 b Costs of Prostate Cancer Treatment 
Optimum treatment and care of any disease should ideally not depend on its cost, but 
unfortunately, due to the lack of unlimited resources we have to prioritize and find the most cost-
effective strategy to manage a particular disease.  Prostate cancer management remains a 
challenge due to the increase in incidence (which is attributable to increased screening and aging 
populations) and the lack of evidence-based treatment strategies. We need randomized clinical 
trials as well as cost-effectiveness studies in order to establish the best treatment for prostate 
cancer according to age, clinical stage, presence of co-morbidities, and many other individual 
characteristics.  Existing studies evaluating the costs of prostate cancer treatment tend to have a 
small sample size and do not comprehensively cover all stages and treatment strategies.[20] A  
comparison of costs of prostate cancer treatment across different countries may be a useful first 
step to tackle the issue at hand.  
I. Costs of prostate cancer care in Europe 
A recent prospective cohort study conducted by Fourcade et al. compared treatment costs 
of prostate cancer in the first year after diagnosis across five European countries.[21]  The mean 
cost per patient was 3256, 5226, 5851, 4057 and 3071 euros for Spain, Italy, France, Germany, 
and the United Kingdom, respectively.[21] The treatment strategies adopted by different 
countries also varied (Figure 3).[21] The average treatment cost per patient was the highest in 
France, and most of the cost was attributable to surgical therapy.  The United Kingdom, on the 
other hand, had the lowest average cost, most of which were accounted for by radiotherapy 
(Figure 3).[21] Follow-up costs or costs due to adverse events were not considered in this study.  
A recent French study estimated that the average 5-year cumulative treatment cost per 
patient was €12,731(in 2008 euros) for the country overall and varied from €11,172 in Tarn to 
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€14,421in Isere.[22] The type of initial treatment (i.e., treatment patients received in the first 6 
months after diagnosis) has a direct impact on the 5-year cumulative cost, which was the highest 
for individuals treated with external beam radiation therapy and lowest for watchful waiting.  
The cost for androgen deprivation therapy started low but became more expensive than radical 
prostatectomy after 39 months of follow up.[22] 
In the United Kingdom, the mean treatment cost per prostate cancer patient during the 5 
years after diagnosis was £7,294 for those diagnosed during 2001 – 2002.[23] Patients were 1.5 
times more likely to undergo radiotherapy than radical prostatectomy. This finding is consistent 
with those reported by Fourcade et al., which indicated that the initial treatment choice for 
prostate cancer was more likely to be radiotherapy in the United Kingdom. 
 
II. Costs of prostate cancer care in North America 
In Canada, total direct cost per 100 days was $C3,289 for the early treatment phase 
(during 12 months after diagnosis), $C1,495 for continuing care, $C5,629 for late care and 
$C16,020 for the last 6 months of life.[24] The average direct healthcare cost per patient was 
$C12,005 during the year after diagnosis and $C20,543 in the last 12 months preceding 
death.[24] The two-year mortality rate of incident cases reduced from 12.5% in 1995 to 8.4% in 
2001, but the rate estimates were based on small sample sizes (4758 to 7159 patients for different 
years) and may not be reliable.[24] Over the same time period, there was an increase in the 
percentage of patients undergoing surgery (from 21.9% to 31.2%) or radiotherapy (from 26.8% 
to 33.3%) in the year after diagnosis, whereas the percentage of patients receiving hormonal 
therapy as primary or adjuvant therapy declined slightly (from 58% to 54.5%).[24]  
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In the United States, a recent economic review estimated that expenditure on prostate 
cancer treatment in 2006 was $9.862 billion, and the average Medicare payment per prostate 
cancer patient in the first year after diagnosis was $11,000.[25] Consistent with other studies, 
cost of prostate cancer care is highly related to the treatment modality chosen.  The average 
prostate cancer-specific 2-year cost was approximately $7595 for watchful waiting and $38,945 
for active treatment.[10]  
III. Regional Variation of Prostate Cancer Treatment in the United States 
Prostate cancer is the most common type of cancer among males in the Unites States 
(US), with approximately 241,750 incident cases in 2012.[26, 27] The incidence of prostate 
cancer varies geographically (i.e., across different states in the US) and over time, which is 
partially attributable to the different utilization of prostate-specific antigen  (PSA) screening test 
across different areas and time periods.[26, 27] The estimated number of deaths from prostate 
cancer in 2012 was 28,170, accounting for 9% of all cancer-related deaths in men.[26] Although 
the number of deaths may seem high, data from 1996 to 2004 show that almost 90% of newly 
diagnosed cases of prostate cancer were detected at the local or regional stage.[27] This along 
with better treatment modalities has contributed to an almost 100% probability of 5 year relative 
survival.[27] This increased survivorship and an aging population will lead to increases in the 
number of people receiving prostate cancer care as well as palliative care for co-morbidities.[28] 
The economic burden posed by prostate cancer can be substantial.  
Studies of the treatment costs for any disease play an important role in determining the 
demand and supply of procedures and help to allocate resources as well as effectively design 
health care services and policies. In the year 1990, the estimated total national health expenditure 
on prostate cancer and its treatment ranged from $1.72 billion to $ 4.75 billion.[19] However, 
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with the advent of newer screening procedures, increased incidence, novel treatment modalities, 
as well as prolonged survival time, the costs have likely been increasing. Rising health care costs 
in the US has brought oncology care under the scrutiny.[19] The cancer costs projected for 2020 
are 157.77 billion in 2010 US dollars if cancer incidence, survival and treatment costs remain the 
same, and the largest percent increase would be in the costs of long-term care for prostate cancer, 
where a 42% of increase is projected.[29]   
Cancer care and its financing will probably chance substantially in the near future, with 
the field of oncology empirically testing models that will reduce costs as well as increase 
quality.[30] One of the dimensions of this issue is the regional variation is the costs of care 
across the US. The Dartmouth Atlas of Healthcare project showed that with respect to the 306 
hospital referral regions in the US, Medicare reimbursements in 2007 varied from about $5,200 
per person in the lowest spending region to more than $17,000 in the highest spending 
region.[31] Fisher and colleagues argue that it is inappropriate to attribute all rising costs to 
technology, as the differences in the costs of care across regions would suggest that physician 
responses and treatment choices in different regions lead to the regional variation in costs.[32] 
Therefore the differences between high spending and low spending regions should be further 
examined in order to identify successful delivery systems and to identify gaps in the systems.[32] 
Any regional difference in costs demonstrates healthcare market inefficiencies.[33] 
Although there is enough evidence regarding regional variation in healthcare spending with 
respect to general healthcare utilization in different US geographic regions, there are relatively 
few studies focusing on the costs of prostate cancer, despite its high incidence and prevalence in 
the US. Table 3 provides a summary of studies assessing regional variation in prostate cancer 
care costs or prostate cancer treatment. A recent cross-sectional study assessing regional 
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variation in cost of prostate cancer care showed that California had the highest mean total cost 
per prostate cancer patient ($12,940), Utah had the lowest expenditure ($4,650), and Washington 
was in the middle ($8,903, p <0.001).[33] Other studies did not directly assess regional variation 
in costs but assessed the geographic variation in prostate cancer treatment and diagnostics 
services.  Radical prostatectomy, radiation therapy and watchful waiting are some of the 
treatment strategies for prostate cancer. A study assessing geographic variation in treatment 
using National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) data 
(1995-1999) concluded that there were significant differences with respect to all treatment 
modalities.[34] For example, Los Angeles had the highest rates of surgery and watchful waiting 
as treatment modalities than other SEER regions, while Detroit had a higher rate of radiation 
therapy.[34] Another study using linked SEER-Medicare data (1983-1994) found that 15.6% of 
prostate cancer patients in Connecticut received radical prostatectomy whereas more than 40% of 
the patients in Utah underwent this procedure.[35] Although the observed geographic differences 
in the rates of radical prostatectomy were significant, the magnitude was considered 
moderate.[35] With respect to radiation therapy, a similar study showed that non-surgically-
treated patients in New Mexico had the lowest rate of radiation therapy (48.7%), while the rate 
for patients in Seattle was greater than 75%.[36] As for the use of hormonal therapy as an 
adjuvant to surgery, it was more common in Iowa [Hazard Ratio (HR) = 1.93, 95% Confidence 
Interval (CI): 1.12-3.32; p-value = 0.019) and New Mexico/Georgia/Hawaii (HR = 1.92, 95% 
CI: 1.09-3.39; p-value = 0.025) than in San Francisco.[37] Another study focused on the imaging 
techniques used for staging (i.e., before prostate cancer treatment) and found that patients 
undergoing radiation therapy were more likely to get staging magnetic resonance imaging, 
computed tomography, bone scans than patients who received prostatectomy.[38] 
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The existing literature demonstrates the regional variation in treatment strategies, but it is 
unclear whether the costs of prostate cancer care also vary geographically.  One might presume 
that significant differences in treatment patterns will translate into differences in costs based on 
choice of drugs, referral for surgery or radiotherapy, referral for additional palliative and end-of 
life care etc.[39] Previous strategies such as “prior authorization” and “reducing fee schedules” 
have been unsuccessful in reducing costs because they do not necessarily target the causative 
factor.[39] In order to reduce the costs pertaining to prostate cancer care, we first need to identify 
whether there are regional variations with respect to the costs of prostate cancer care, preferably 
in a prospective cohort study that follows up each prostate cancer patient longitudinally after 
diagnosis.   If such variations are observed, it would then be important to evaluate the 
determinants of variations and to derive health service and policy amendments that might help us 
to curb prostate cancer costs and reduce variation in practice, costs as well as quality and health 
outcomes.  
2.3 Costs of Prostate Cancer Care in Asia and Africa 
Since PSA-based prostate cancer screening is not common in Asian and African 
countries, we do not know the true incidence and prevalence of the disease.[40] As a result there 
are no specific cost studies with respect to prostate cancer care in these countries.   
2.4 Conclusion 
There are substantial global variations in the incidence, mortality, patterns of care, and 
costs of care with respect to prostate cancer.  To a large extent, the variations can be attributed to 
differences in health systems, screening and diagnostic resources, and clinical practices.  I 
focused on direct costs, as they are easier to define and evaluate and also have more direct 
implications for health policy.  Most of the cost studies to date were conducted in the developed 
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countries, where prostate cancer is a major public health burden.  Given the continuous increase 
of prostate cancer morbidity and mortality in the developing countries, it is important to develop 
evidence-based guidelines for the screening, diagnosis and treatment of prostate cancer so the 
entire world prostate cancer community could benefit.      
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Chapter 3: Regional Variation in the Treatment Costs of Prostate Cancer Patients in the 
Medicare Population 
 
 
3.1 Introduction 
 
Prostate cancer is the most common type of cancer among males in the Unites States 
(US), with approximately 241,750 incident cases in 2012.[26] Due to the high incidence, long 
survival, and multiple treatment modalities, prostate cancer poses a substantial economic burden 
to the healthcare system.  Although there is enough evidence regarding regional variation in 
healthcare spending with respect to general healthcare utilization in different US geographic 
regions,[41, 42] there are relatively few studies focusing on the costs of prostate cancer, despite 
its high incidence and prevalence in the US.  
Using data from the 2004 Healthcare Cost and Utilization Project National Inpatient 
Sample, Makarov et al. observed substantial regional variation in the costs of prostate cancer 
care, but the cross-sectional nature of the study made the findings difficulty to interpret.[33] 
Other studies did not directly assess regional variation in costs but evaluated the geographic 
variation in the diagnosis and treatment of prostate cancer.[34-38]  
In order to reduce the costs pertaining to prostate cancer care, we first need to identify 
whether there are regional variations with respect to the costs of prostate cancer care, preferably 
in a prospective cohort study that follows up each prostate cancer patient longitudinally after 
diagnosis.   If such variations are observed, it would then be important to evaluate the 
determinants of variations and to derive health service and policy amendments that might help us 
to curb prostate cancer costs and reduce variation in practice, costs as well as quality and health 
outcomes. The present study was conducted in a large cohort of recently diagnosed and treated 
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prostate cancer patients in the Medicare population to address these research questions and to 
inform health policy decisions.  
 
3.2 Methods 
3.2a Study Sample 
This study used the National Cancer Institute’s Surveillance, Epidemiology and End 
Results (SEER)-Medicare linked database, which linked the Medicare claims and cancer 
diagnosis-related records of Medicare beneficiaries who were diagnosed with cancer in the 
SEER regions. The linked data set allowed us to select prostate cancer cases as well as controls 
from a random 5% sample of the Medicare beneficiaries who reside in the 17 SEER areas.  
Patient level data are available for socio demographic and cancer characteristics, including age at 
diagnosis, race, median household income at the zip code level, tumor stage, PSA level, and 
Gleason score. We used beneficiary zip code to link the men to hospital referral regions (HRRs) 
as defined by the Dartmouth Healthcare Atlas.[31, 43]  
We identified prostate cancer patients using SEER-Medicare database and their matched 
controls using the 5% random sample of non-cancer Medicare beneficiaries residing in the SEER 
areas. This allowed us to isolate total cancer-related expenditure by calculating the difference in 
expenditures between cancer patients and the controls. Our “case” group consisted of men who 
where 67- 94 years and were diagnosed with first primary localized prostate cancer during 2003-
2007. In order to allow for two full years of claims history to accurately assess comorbidity 
status and pre-cancer costs we chose 67 years of age as the lower limit for inclusion. The 
inclusion criteria of patients were to have known months of diagnosis, zip codes (for linkage to 
HRRs) and continuous enrollment in both Medicare Parts A and B during the claims assessment 
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period (two years prior to diagnosis through one year after diagnosis). We excluded patients who 
had a previous history of cancer, could not be linked to a HRR based on zip code, did not have 
continuous Medicare Parts A and B coverage, or were enrolled in a managed care plan during the 
claims assessment period (Figure 4). 
Each man identified as a prostate cancer “case” was matched to a man without cancer 
who served as a “control” from the Medicare 5% random sample of non-cancer beneficiaries. An 
index pseudo date of diagnosis for controls was assigned as the first day of a randomly selected 
month in which the control was alive and met the same enrollment criteria used for cases except 
for prostate cancer diagnosis. Cases and Controls were matched by age at time of diagnosis for 
cases and index date for controls (in quartile), comorbidity (yes/no), race (white, black and other) 
and year of diagnosis. The Yale Human Investigation Committee determined that this study did 
not directly involve human subjects. 
 
3.2 b Measures 
This analysis was conducted from the payer’s perspective since in health services 
research Medicare payments are considered a good proxy for true economic costs. The data 
sources for Medicare expenditures were Medicare Standard Analytical Files and included 
payments in Medicare Provider Analysis and Review (inpatient), Carrier Claims (individual 
physician), Outpatient (hospital-based outpatient), Home Health Agency, Durable Medical 
Equipment and Hospice files. Consistent with previous studies,[44, 45] we adjusted for 
geographic variation in input prices of care across SEER regions using the Medicare Capital 
Geographic Adjustment Factor for Part A services and the Geographic Practice Cost Index for 
Part B services.[46, 47] In addition, we used the Medicare Prospective Payment System Hospital 
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Input Price Index and the Medicare Economic Index to adjust all expenditures on Part A and Part 
B services, respectively, to 2009 U.S. dollars.[48] 
For each beneficiary in our sample, we calculated Medicare expenditures during the 
initial phase of care as the sum of all Medicare payments in these files over the period from two 
months prior to prostate cancer diagnosis (for cases) or index date (for controls) through 12 
months after the diagnosis or index date.[49] Medicare expenditures on surgery, radiation 
therapy, biopsy, hormone therapy and imaging services over the same time period were also 
assessed separately (for cases only). International Classifications of Diseases, 9th edition (ICD-9) 
procedure codes, Current Procedural Technology (CPT) codes, and Healthcare Common 
Procedure Coding System (HCPCS) codes were used to identify claims corresponding to these 
services. 
  We identified comorbid conditions using ICD-9 codes. Diagnosis codes appearing on an 
inpatient claim or at least two outpatient claims billed more than 30 days apart during the time 
period 24 through three months prior to diagnosis (cases) or index date (controls) were selected. 
A modified list of conditions suggested by Elixhauser et al. was used.[50] Patients were coded as 
having 0, 1-2, or at least 3 conditions. Other measures, including patient age, race (all subjects) 
and tumor stage, PSA level, Gleason score (cases only) were directly obtained from the SEER-
Medicare data and the 5% random sample of non-cancer Medicare beneficiaries for cases and 
controls, respectively, reflecting patient characteristics at the diagnosis/index date. 
3.2c Statistical Analysis 
Cancer-related costs for each patient and each HRR were estimated by calculating the 
difference in its total Medicare expenditure between cases and controls. Hierarchical generalized 
linear models (HGLMs) with a log link function and gamma distribution were used for risk 
  
adjustment. To eliminate the influence of extreme values and outliers,
expenditures by assigning the 97.5
We used sequential models in order to determine the relative contribution of various 
patient characteristics to the overall variation in Medicare expenditure on prostate cancer care. 
We first estimated an unconditional model with just an intercept (Model 0), and then added 
patient demographic and non-cancer related health characteristics (Model 1), including patient 
age (in quartile), race (white, black, or other), comorbidities (Elixhauser score 0,1
calendar year of diagnosis (for cases) or index date (for controls). In the next model, we added 
prostate cancer related factor that included PSA (<=10, 10.1
(<=6, 7, >7, unknown) and stage (T1, T2, T3 and T4, unknown) (Model 2). Subsequently, we 
examined whether addition of active treatment used versus watchful waiting may explain 
variation in cancer care costs (Model 3), and f
was added to Model 3 (surgery, radiotherapy, hormone therapy, biopsy and imaging services)
(Model 4).  
For the null (Model 0) and 
each patient his “expected” Medicare expenditure, i.e., the predicted expenditure conditional on 
the HRR random effect being zero. Then for a given HRR, we estimated its adjusted per patient 
total Medicare expenditure on prostate cancer care as: 
 
where  is the mean observed Medicare expenditure calculated over all cases in HRR
 is the mean observed Medicare expenditure calculated over all controls in HRR
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-20, >20, unknown), Gleason score 
or the last model the specific treatment strategy 
multivariable models (Model 1, 2, 3, 4) we first calculated for 
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-2, or 3+), and 
) 
i, 
i, is 
  
the mean expected Medicare expenditure calculated over all cases in HRR
expected Medicare expenditure calculated over all controls
the mean observed Medicare expenditure calculated over all cases and controls, respectively, in 
the entire sample. This measure reflects variation across HRRs in their per patient Medicare 
expenditure for prostate cancer-related care after adjusting for selected patient characteristics. 
Analogous risk adjustment models were estimated for Medicare expenditure on five 
major components of prostate cancer care (i.e., surgery, 
and imaging services), using only data from the cancer cases. Radiation therapy only referred to 
those with identified modalities, i.e., intensity modulated radiation therapy (IMRT), externa
beam radiation therapy (EBRT), stereotactic radiosurgery (SRS
brachytherapy. However, because not all cancer patients received each of these 
treatments/services, a large proportion of the cases had zero values on these component 
expenditures. Therefore we adapted the HGLMs by integrating them wi
while allowing for correlated HRR random effects to account for the “semi
of these expenditure data.[54] We used these models to ca
“expected” Medicare expenditure based on his predicted probability of having non
expenditure and his predicted expenditure conditional on having non
setting the HRR random effect at zero). Th
component of prostate cancer care for HRR
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refer to the jth component of cancer care. 
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Thus estimated Medicare expenditures were summarized across HRRs. We divided the 
total estimated Medicare expenditures into quintiles. Subsequently, we assigned HRRs to the five 
HRR level related expenditure quintiles based on per patient total expenditures on prostate 
cancer treatment from our null model. The degree of regional variation in total expenditure, as 
well as the five components of care, was evaluated by comparing the corresponding mean 
estimates across the HRR level related expenditure quintiles. Estimates of mean expenditure in 
each quintile were weighted by the number of prostate cancer patients in each HRR. 
Descriptive statistics were calculated to summarize the characteristics of patients and 
HRRs in our sample cohort using mean (standard deviation [SD]) for continuous variables and 
frequencies and percentages for categorical variables.  Estimates with p values less than 0.05 
were considered statistically significant. All data analysis was performed using SAS (version 9.2, 
SAS Inc, Cary, NC).  
 
3.3 Results 
3.3a Sample Characteristics 
Prior to our final cohort, 64,900 cases with matched controls were selected out of 68,466 
cases. (Figure 4) The final cohort for our analysis included a total of 46,077 cases of localized 
prostate cancer and an equal number of controls (after excluding non-localized cases and 
unknown variables). They came from 96 HRRs across the country out of which 9 HRRs had less 
than 25 patients. Almost 54% of the patients were ≤ 74 years of age while 46% where older than 
75. Approximately eighty-two percent of the sample was white. Fifty one percent of the cases 
had no comorbid conditions, while 35.92 % had one or two other diseases and 12.85 % had three 
or more conditions.  Fifty four percent of the prostate cancer patients in our sample were 
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diagnosed at stage I, 17.52 % were diagnosed at stage II, and 2.38% were diagnosed at stage III 
or higher.  Fifty eight percent of the cases had a serum PSA level between 0 and 10 at the time of 
diagnosis and 44% of patients had a Gleason score between 0 and 6 (both inclusive) (Table 1). 
 
3.3b Regional variation in Medicare expenditure for prostate cancer treatment 
For the 96 HRRs in our analysis, the total Medicare expenditure on prostate cancer-
related care averaged $15,567 per patient over the 14-month initial phase of care (SD = $2,458.8) 
and ranged from $5,289 to $25,830 across the 96 HRRs.  Likewise, we observed substantial 
variation in Medicare expenditures on the five main components of prostate cancer care. With 
mean expenditures at $1,707 (SD=693.0), 10,216(SD=2,351.5), 758 (SD=213.0), 1,063 (SD=205.6), 
284 (SD=78.4), respectively, per patient expenditures on surgery, radiotherapy, hormone therapy, 
biopsy, and imaging services ranged from $1,937 to $1,305 (the lowest quintile had higher 
surgery cost), $7,948 to $13,522, $1,010 to $1,186, $706 to $763, and $216 to $337[X1] , 
respectively, across the five HRR level related expenditure quintiles. 
Differences in patient demographics, comorbidity, and cancer specific characteristics, as 
well as treatment type, explained part of the variation in Medicare expenditures for prostate 
cancer treatment across HRRs. Adjustment of patient age, race, comorbidity and year of 
diagnosis (Model 1) increased the difference in mean expenditure between the highest and 
lowest quintiles from $6,664 to $6,936 (an increase of $272 or 4.1%). Further adjustment of 
prostate cancer related characteristics such as PSA level, Gleason score and tumor stage (Model 
2) increased the difference by another 1.5%.  In contrast, adding the indicator for whether a 
patient had any active therapy or had “watchful waiting” as the initial treatment strategy (Model 
3) considerably attenuated the difference in expenditures across lowest and highest HRRs to 
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$5,358 (reduction by 23.9% compared to Model 2). Subsequently, accounting for the type of 
treatment (surgery, radiotherapy, biopsy, hormonal therapy and imaging) (Model 4) marginally 
increased the difference in mean expenditures between the highest and lowest quintiles to $5,403 
(i.e., an additional 0.8% increase compared to Model 3).  
The adjustment of patient demographics, comorbidity and cancer specific characteristics 
increased the mean difference in radiotherapy expenditure across the HRRs – increasing it from 
$5,574 between the highest and lowest quintiles to $5,803.  In addition, after adjusting for use of 
active treatment versus watchful waiting (Model 3) and adjusting for specific type of treatment 
(Model 4) the mean difference between highest and lowest quintile for radiotherapy did not 
reduce considerably ($3,611). That means that the difference in costs between highest and lowest 
quintiles reduced at each model for every treatment strategy except for radiotherapy. To further 
examine the role of treatment type in influencing variations in Medicare expenditure, Figure 2b - 
6b showed the average proportion of prostate cancer patients receiving each of the prostate 
cancer treatments across the HRR level related expenditure quintiles and the average expenditure 
per patient among recipients. There was minimal difference in rates of surgery, hormone, biopsy 
and utilization of imaging services across HRRs, and Medicare expenditures on these were 
relatively stable across the HRR level related expenditure quintiles. In contrast, receipt of various 
types of radiation therapies varied considerably across the HRR level related expenditure 
quintiles, as did the average expenditure per user. Higher expenditure HRRs were more likely to 
use expensive IMRT and brachytherapy than traditional EBRT. In particular, utilization rate of 
IMRT increased from 18.4% in the lowest quintile to 39.1% in the highest quintile.  
Considerable regional variations in costs remained after the adjustment of patient 
characteristics and the utilization of different treatments. Compared to the unconditional model 
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(Model 0), our fully adjusted model (Model 4) only reduced the difference in mean expenditures 
between the highest and lowest HRR level related expenditure quintiles from $6,664 to $5,403 
(i.e., a decrease of 19%). Total cancer-related expenditure still varied from $12,370 per prostate 
cancer patient in HRRs in the lowest expenditure quintile to $17,773 per patient in HRRs in the 
highest expenditure quintile, leaving 81% of the difference unexplained (Table 5, Figure 5). 
 
3.4 Discussion 
This study demonstrated considerable regional variation in Medicare expenditures on 
prostate cancer care for fee-for-service beneficiaries. The difference between lowest ($12,572) 
and highest cost quintile ($19,236) was $6,664. Among the five major categories of treatments, 
the specific types of radiotherapy appeared different across regions with different levels of 
overall cost of prostate cancer care.  However, 81% of the variation in overall cost still remained 
unexplained after adjusting for patient demographics, prostate cancer specific factors and 
treatment.  
Earlier research by Fisher et al. reported a 59% difference in per capita Medicare 
spending on physician and hospital services for colorectal cancer patients between high-spending 
and low-spending HRRs (measured by Medicare per capita end-of-life spending). [55, 56] 
Skolarus et al. (2010) found an almost $4,000 difference in per capita Medicare payments for 
patients with early stage bladder cancer over the first two years after diagnosis between high 
spending and low spending hospital service areas (HSAs) ($5,594 versus $9,554).[55, 56]  As for 
prostate cancer treatment costs, Makarov et al. demonstrated that the average cost of radical 
prostatectomy ranged from $4,650 in Utah to $12,490 in California.[33] In the present study, we 
assessed the variation in prostate cancer treatment costs using recent SEER-Medicare data (2003-
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2007). HRRs with the highest cost quintiles had average cost that was 53% higher than that of 
HRRs with the lowest cost quintiles.  
The regional variation in prostate cancer treatment costs is concerning since one would 
presume that treatment in the first year after diagnosis would be similar across all regions. Some 
studies showed a variation in utilization of treatment strategies like radical prostatectomy, 
radiation therapy and hormonal therapy even after adjusting for patient and prostate cancer 
characteristics. For example, large variations in the utilization of surgery, radiation and watchful 
waiting have been reported.[34] The rate of radical prostatectomy ranged from 15.4% to 40%, 
while the rate of radiation therapy varied from 48.6% to 75%.[35, 36]  In our study, we classified 
HRRs into quintiles based on the overall HRR-specific costs of prostate cancer care and 
observed minor variations in the utilization of all treatment strategies except for radiation 
therapy. The cost differences between the highest and lowest quintiles of HRRs level related 
expenditure considerably reduced in Model 4 for all treatment strategies except for radiation 
therapy, indicating that demographics and utilization did not sufficiently explain the cost 
differences. 
Since patients with cancer typically see multiple providers (e.g., surgeon, radiation 
oncologist, primary care physician, etc.), much of the variation in utilization and costs may be 
explained by provider choices. Providers may play an important role in influencing the type and 
amount of treatment received by cancer patients and carry important implications on cost. There 
is tremendous debate regarding the best initial treatment strategy for localized prostate cancer, as 
no strategy (surgery, radiation, hormone, watchful waiting) has been proved to have better 
outcomes that the other options.[57] Further research is needed to fully assess the role of 
providers in influencing cancer care expenditures across geographic regions. 
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Attributes of the HRRs (e.g., availability of specialists and equipment) may also affect 
resource utilization and selection of treatment modalities. For example, Mullins et al. (2004) 
found evidence for variability in annual ambulatory costs of cancer care across urban, suburban 
and rural areas in Maryland, particularly for prostate cancer. Future research linking 
characteristics of geographic regions to spending levels, as well as more in-depth comparison of 
low spending versus high spending regions, would be helpful in identifying the gaps. 
We are cognizant of the fact that by focusing on expenditures alone, the current study 
cannot fully inform policy discussion on value of care. In an ideal situation, data on costs should 
be considered in conjunction with quality and outcome measures. Higher Medicare spending in 
certain regions for prostate cancer treatment may either demonstrate inefficiencies or it might be 
resulting in better outcomes. These two mechanisms need to be distinguished as they have 
different policy implications. Few studies have examined the relationship between costs and 
outcomes of care in cancer patients and report inconsistent results. Future research characterizing 
geographic variation in value of care, i.e., examining cost patterns in conjunction with patient 
outcomes, would provide the most useful information to assist policy discussion.  
Other limitations of the study should be acknowledged as well. First, our analysis was 
based on linked SEER-Medicare data. Therefore, our findings are only applicable to men over 67 
with prostate cancer residing in the SEER registry regions. They may not be generalizable to 
younger patients with prostate cancer or patients located in other parts of the country and not 
participating in the SEER registry. On the other hand, prostate cancer is more common among 
older men, and the population-based SEER registry covers approximately 28% of the US 
population. Second, our measurement of service utilization and comorbid conditions relied on 
claims data, so it is likely that errors or omissions in billing codes might have occurred. This 
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could have limited our ability to adequately adjust for patients’ clinical factors. However, we 
adopted validated algorithms whenever possible to reduce this possibility. Third, we only tallied 
Medicare Part A and Part B payments and did not capture other costs such as orally administered 
prescriptions, transportation, and loss of productivity. Nevertheless, in health services research, 
Medicare payments are considered a good proxy for true economic cost.[44] 
3.5 Conclusion 
In summary, using recent SEER-Medicare data for patients with localized prostate 
cancer, we identified considerable regional variation in Medicare spending on prostate cancer 
care during the 14-month initial phase of care. Patient demographic and clinical characteristics 
did not explain this variation, while the use of active treatment versus watchful waiting and the 
utilization of specific treatment strategies explained a relatively small percentage of the 
variation.  Substantial regional variation in the costs of prostate cancer care remained after 
controlling for patient and treatment factors, calling for continued effort in searching for key 
contributors to the variation. Future research investigating provider and regional characteristics 
that might have contributed to such geographic variation in prostate cancer costs and integrating 
both cost and patient outcome data will provide better evidence in order to inform policy. 
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Appendix of Tables 
 
 
Table 1. Rank of Prostate Cancer as Cause of Death (Comparison between Global Burden 
Disease study regions in 1990 and 2010) [12] 
GBD Regions Rank in 
1990 
Rank in 2010 
Asia Pacific, High Income 26 16 
Asia, Central 39 40 
Asia, East 60 43 
Asia, South 68 66 
Asia, Southeast 57 42 
Australasia 6 5 
Caribbean 11 5 
Europe, Central 14 11 
Europe, Eastern 25 18 
Europe, Western 7 6 
Latin America, Andean 23 11 
Latin America, Central 21 11 
Latin America, Southern 13 7 
Latin America, Tropical 23 10 
North Africa / Middle East 37 27 
North America, High Income 7 8 
Oceania 47 41 
Sub-Saharan Africa, Central 55 50 
Sub-Saharan Africa, East 59 47 
Sub-Saharan Africa, 
Southern 
34 24 
Sub-Saharan Africa, West 56 42 
Mean (of all regions) 36 28 
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Table 2. Comparison between the United States and other industrialized nations with 
respect to costs of prostate cancer screening, diagnosis and staging[17] 
  Studies in the United 
States 
Studies in other 
industrialized nations 1 
  Mean Cost (in 2003 $) Mean Cost (in 2003 $) 
Screening PSA testing 37.65 30.92 
 Digital rectal examination 31.77 33.56 
Diagnostic Urological examination 76.91 97.06 
 Transrectal ultrasound 237.15 103.77 
 Biopsy 392.83 164.92 
Staging Pathological 94.14 139.04 
 Clinical 736.56 306.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                        
1 Canada, Sweden, the United Kingdom, Australia and Japan 
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Table 3: Review of studies addressing regional variation in prostate cancer care and prostate cancer treatment costs 
Study Name Aim Methods Findings 
Harlan et al; 1995 To examine the variations in the 
use of radical prostatectomy and 
radiation by geographic area, 
age, and race. 
Data set: SEER; 1984-1991 (including 9 
SEER regions) 
Sample: 67,693 men with localized and 
regional prostate cancer were available 
for analysis 
Statistical method: 
The Cochran-Mantel-Haenzel for test of 
general association and for trends  
-In 1991,in Seattle,WA, and Utah, the age-
adjusted proportion of men with 
local/regional disease treated with radical 
prostatectomy was more than twice that of 
Connecticut men.  
-By 1991, the largest difference in the 
proportion that received radiation therapy 
was be- tween San Francisco/Oakland, CA 
(34.5%), and Utah (16.6%), at slightly less 
than 18% (P < .001). 
Lai et al; 2000 To assess the extent to which 
demographic factors explain the 
phenomenon of geographic 
variability in the use of radical 
prostatectomy. 
Data set: SEER  (1983-1994) 
Sample: 112,475 patients with non-
metastatic (localized and regional) 
prostate cancer who had SEER grade 
codes of 1, 2, or 3. 
Statistical method: Logistic regression  
-Connecticut had the lowest rate of radical 
prostatectomy (15.6%) whereas more than 
40% of the patients in Utah underwent this 
procedure. 
-The observed geographic differences in the 
rates of radical prostatectomy, although 
statistically significant, were relatively 
modest 
Lai et al; 2001 To examine the geographic 
variation in the use of radiation 
to treat non-metastatic prostate 
cancer and to identify factors 
that explain the variation in the 
United States. 
Data set: SEER; 1983- 1996 
Sample: 48,785 prostate cancer patients 
Statistical method: Logistic regression, 
nonparametric logistic regression and  
Univariate logistic regression  
Patients in different geographic areas had a 
different likelihood of being treated with 
this procedure. Non-surgically-treated 
patients in New Mexico had the lowest rate 
of radiation therapy (48.7%), the rate for 
patients in Seattle was greater than 75%. 
Saigal et al; 2002 To measure the national practice 
variations in imaging studies 
performed for men newly 
diagnosed with clinically 
localized prostate cancer. 
Data set: Medicare administrative data 
reporting on healthcare services 
delivered (1991-1996) from the Health 
Care Financing Administration (HCFA) 
Sample: 17,586 patients were identified 
by claims indicating a new diagnosis of 
prostate cancer verified by tissue 
biopsy. 
Statistical method: Multivariate 
logistical regression analysis. 
-Men receiving RT as their primary 
treatment were significantly more likely to 
undergo a staging CT scan than those 
receiving RP, regardless of geographic 
region 
- Patients in the Midwest were half as likely 
to undergo MRI (OR 0.53, 95% CI 0.23 to 
0.83) compared with patients in the South  
-Patients in the Midwest and Northeast had 
significantly higher CT use (Midwest OR 
1.37, 95% CI 1.29 to 1.45; Northeast OR 
1.58, 95% CI 1.50 to 1.66), and those in the 
West had significantly less CT use (OR 
  34
0.79, 95% CI 0.69 to 0.89). 
Krupski et al; 2005 To examine geographic and 
socioeconomic variation in the 
primary treatment of men with 
prostate cancer during the era of 
prostate-specific antigen testing. 
Data set: SEER data; 1995-1999 and US 
Census 2000 
Sample: 96,769 prostate cancer patients 
Statistical method: Multinomial logistic 
regression analysis with watchful 
waiting as the referent group to 
investigate a link between the likelihood 
of primary treatment and demographic 
variables. In addition to age, they 
included geographic location and grade 
as covariates. 
 
 
-There was a significant geographic 
variation nationwide in surgical, radiation, 
and watchful waiting treatment rates (P 
<.0015).  
-Patterns noted 10 years ago, such as higher 
surgical rates in western regions, persisted 
Coopersberg et al; 2007 To quantify trends in the 
regionalization of inpatient care 
for urological oncology in a 
national administrative database. 
Data Set: Nationwide Inpatient Sample 
(NIS) data set of the Health Care 
Utilization Project ;1988-2002 
Sample: 178,210 underwent radical 
prostatectomy at total of 2,065 hospitals 
and 146,311 were admitted for non-
operative management at a total of 
2,775 hospitals. 
Statistical Method: Cochrane-Hanzel 
method test was used to analyze trends 
over time. Plotting of the trends was 
done using linear regression. 
-The percent of prostate cancer surgical 
cases discharged from High volume 
hospitals (HVHs) defined as more than 26 
cases of surgery annually was essentially 
constant during the study period at 76%, 
while the percent of nonsurgical prostate 
cancer cases discharged from HVHs 
decreased slightly. 
-In the Northeast, West and Mid-west 
region the trend for the percent of 
discharges from HVHs increased from 1988 
to 2002 for surgical and nonsurgical 
admissions for prostate cancer (p < 0.0001).  
Makarov et al; 2010 To determine whether state level 
variation in the cost of radical 
prostatectomy exists and 
whether this variation could be 
explained by adjusting for 
covariates associated with cost 
Data set: 2004 Healthcare Cost and 
Utilization Project National Inpatient 
Sample 
Sample: 9,917 men, 40 years old or 
older with a diagnosis of prostate cancer 
who underwent radical prostatectomy 
without cystectomy. 
Statistical method: Simple linear 
regression for continuous variables and 
ANOVA for categorical variables 
 
 
-There was significant unadjusted statewide 
variation in Total Cost (TC). In the 
unadjusted model compared with the mean 
TC in Washington (reference) the highest 
cost state was California and the lowest was 
Utah ($8,903 vs $12,490 and $4,650, 
respectively, p <0.0001). 
-In the fully adjusted model with 
Washington as the reference the highest cost 
state was Colorado and the lowest was New 
Jersey ($10,751 and $5,899, respectively 
with p <0.001) 
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Williams et al; 2011 To identify the costs of adjuvant 
therapies following radical 
prostatectomy (RP) and factors 
associated with their receipt. 
Data set: SEER- Medicare; 2004-2006 
Sample: 4247 men who received RP out 
of which 600 received adjuvant 
therapies 
Statistical method: Unadjusted analysis 
using the Pearson chi-square statistic 
and Cox multivariable regression model  
-Geographic variation for utilization of 
adjuvant therapies, with the San Jose versus 
Detroit region having the highest versus 
lowest utilization rates (20.4% vs 9.9%, 
P<0.001)  
-In adjusted analysis there was greater use 
of adjuvant therapies in Iowa (HR, 1.93; 
95% CI, 1.12-3.32 [P = 0.019]) and New 
Mexico/Georgia/Hawaii (HR, 1.92; 95% CI, 
1.09-3.39 [P = 0.025]) versus San Francisco 
SEER regions. 
Nambudiri et al, 2012 To examine the variation in 
prostate cancer treatment in the 
Veterans Health Administration 
(VHA). Also compared older 
men in VA to men in fee-for 
service Medicare 
Data Set: Veterans Affairs (VA) Central 
Cancer Registry, SEER- Medicare; 
2001-2004 
Sample: Within-VHA analysis included 
32,533 veterans of all ages diagnosed at 
VHA facilities. for the comparative 
analyses consisted of 19 210 veterans 
aged < 65 years and 65 751 Medicare 
beneficiaries aged <65 years. 
Statistical Method: Multinomial logistic 
regression analysis.   
-Facilities without urologists had the 
greatest rates of neither treatment (44.5%), 
and those with urologists but no residents 
had the greatest radiotherapy rates (41.1%) 
and lower prostatectomy rates than facilities 
with no urologists (22.9% vs 25.5% P < 
.004). Variation in treatment by facility not 
explained by patient or facility 
characteristics.  
-The rates of prostatectomy (12.1% vs 
15.8%) and radiotherapy (39.7% vs 52.0%) 
were lower in the VHA than in fee-for-
service Medicare, and the rate of receiving 
neither therapy was much greater in the 
VHA (48.2% vs 32.2%; P < .001;) 
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Table 4: Characteristics of Prostate Cancer Patients and Controls 
 
Prostate Cancer cases  
(n= 46,077) 
Controls 
 
 
n (%) n (%) 
Age at diagnosis      
 67- 70   13263 28.78   
70-74 12187 26.45   
75-79 11711 25.42   
80+ 8916 19.35   
 
    
Comorbidity     
0 23604 51.23 23606 51.23 
1-2 16550 35.92 14988 32.53 
3+ 5923 12.85 7485 16.24 
 
    
Race     
White 38078 82.64   
Black 4701 10.2   
Other 3298 7.16   
 
    
Year of diagnosis     
2004 11582 25.14   
2005 11205 24.32   
2006 11748 25.5   
2007 11542 25.05   
 
    
PSA     
-10 27169 58.96   
10.1-20 7071 15.35   
20.1+ 4174 9.06   
Unknown 7663 16.63   
 
    
Gleason Score     
0-6 20494 44.48   
7 16897 36.67   
>7 7512 16.3   
Unknown 1174 2.55   
 
    
Stage     
T1 24931 54.11   
T2 8072 17.52   
T3/4 1098 2.38   
Unknown 11976 25.99   
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Table 5: Mean prostate cancer related costs across HRRs ($) 
 Model 0 Model 1 Model 2  Model 3 Model 4 
1st quintile 12572 12599 12654 12531 12370 
2nd quintile 14089 14330 14331 14097 13870 
3rd quintile 14977 15284 15215 14829 14780 
4th quintile 16859 17011 16966 16023 15691 
5th quintile 19236 19535 19692 17889 17773 
 
Difference in highest and lowest quintile 6664 6936 7038 5358 5403 
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Table 6: Mean prostate treatment cost per patient across HRRs ($)  (Note: each treatment was 
categorized by its own distribution) 
 model 0 model 1 model 2 model 3 model 4 
Surgery      
1st quintile 1756.27 1710.09 1641.53 1717.69 1626.18 
2nd quintile 1767.70 1780.85 1750.07 1683.45 1634.17 
3rd quintile 2185.91 2195.37 2171.20 2237.53 1556.23 
4th quintile 1583.36 1540.12 1657.49 1504.70 1578.16 
5th quintile 1240.64 1267.65 1266.14 1227.37 1619.27 
      
Radiation Therapy      
1st quintile 7494.82 7494.13 7352.16 7641.74 8145.02 
2nd quintile 8640.38 8719.01 8647.16 8700.08 8929.39 
3rd quintile 9689.05 9789.32 9864.69 9666.01 9818.98 
4th quintile 11263.97 11241.46 11332.01 10723.87 10792.85 
5th quintile 13773.08 13777.74 14031.29 12718.62 12458.26 
      
Biopsy      
1st quintile 1218.81 1178.54 1171.03 1246.92 1043.71 
2nd quintile 1021.36 1087.09 1083.25 1009.41 1119.95 
3rd quintile 1004.70 995.03 1050.17 1043.97 946.21 
4th quintile 1064.77 1050.59 998.07 989.89 1078.52 
5th quintile 997.22 1019.76 1023.66 1045.22 1041.26 
      
Hormone therapy      
1st quintile 491.23 498.03 489.76 492.10 275.58 
2nd quintile 635.19 617.21 613.68 619.47 307.18 
3rd quintile 743.14 705.77 698.72 707.76 323.65 
4th quintile 844.75 822.21 821.15 825.85 345.80 
5th quintile 1071.13 1068.67 1072.92 1081.27 413.04 
      
Imaging      
1st quintile 186.87 183.10 181.32 183.10 219.81 
2nd quintile 240.42 239.28 234.99 236.04 257.87 
3rd quintile 273.71 277.30 270.94 267.52 282.44 
4th quintile 307.25 309.66 311.66 308.18 312.64 
5th quintile 409.75 407.81 422.40 402.09 350.26 
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Table 7: Mean prostate treatment cost and prevalence of treatment according to HRR level total 
prostate cancer – related cost  (categorized in quintiles based on total prostate cancer-related cost)- 
Model 0 
 
1st quintile 
(Lowest) 2nd quintile 3rd quintile 4th quintile 
5th quintile 
(Highest) 
 
Cost ($)      
Total  12572 14089 14977 16859 19236 
Surgery 1937 1632 2156 1487 1305 
RT 7948 9342 9034 11200 13522 
Biopsy 1010 997 977 1150 1186 
Hormone 706 757 778 783 763.28 
Imaging 216 257 279 327 337 
Other 756 1102 1753 1912 2122 
 
Prevalence (%)      
Active treatment 62.5 59.8 62.4 66.5 68.1 
Surgery  19.1 15.6 21.1 14.2 12.8 
RT 44.6 45.1 42.8 53.1 56.1 
  Brachy 22.4 13.5 13.7 21.6 27.2 
  IMRT 18.4 28.8 27.8 32.3 39.1 
  EBRT 12.9 12.0 8.6 9.8 8.3 
  SRS 0.3 0.1 0.3 0.3 0.5 
   Proton 0.6 0.4 1.0 1.5 0.4 
Biopsy 89.9 88.1 88.9 90.6 90.7 
Hormone  36.8 38.6 40.6 41.8 44.0 
Imaging  53.8 57.4 59.8 67.0 67.9 
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Table 8: Mean prostate treatment cost and prevalence of treatment according to HRR level total 
prostate cancer – related cost  (categorized in quintiles based on total prostate cancer-related cost)- 
Model 1 
 
1st quintile 
(Lowest) 2nd quintile 3rd quintile 4th quintile 
5th quintile 
(Highest) 
 
Cost ($)      
Total  12599 14330 15284 17011 19535 
Surgery 1861 2030 1866 1533 1234 
RT 8006 8829 9756 11061 13597 
Biopsy 982 1001 1016 1140 1195 
Hormone 677 740 762 774 762 
Imaging 208 275 273 320 343 
Other 865 1456 1612 2181 2405 
 
Prevalence (%)      
Active treatment 60.9 62.0 61.9 67.2 67.3 
Surgery  19.2 19.7 17.0 15.5 11.4 
RT 42.8 43.4 46.1 52.7 56.5 
  Brachy 21.4 13.8 13.6 21.7 27.4 
  IMRT 17.9 26.9 31.0 31.9 39.2 
  EBRT 11.8 10.5 11.1 8.6 9.3 
  SRS 0.3 0.1 0.3 0.3 0.5 
   Proton 0.7 0.8 0.6 1.6 0.2 
Biopsy 88.1 89.6 89.1 90.5 90.8 
Hormone  35.0 41.5 39.4 41.5 44.5 
Imaging  51.7 59.7 59.6 65.8 69.3 
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Table 9: Mean prostate treatment cost and prevalence of treatment according to HRR level total 
prostate cancer – related cost  (categorized in quintiles based on total prostate cancer-related cost)- 
Model 2 
 
 
1st quintile 
(Lowest) 2nd quintile 3rd quintile 4th quintile 
5th quintile 
(Highest) 
 
Cost ($)      
Total  12654 14331 15215 16966 19692 
Surgery 1745 2154 1761 1562 1186 
RT 8108 8697 9775 10908 13911 
Biopsy 975 1044 974 1163 1164 
Hormone 661 763 716 771 786 
Imaging 207 271 269 316 357 
Other 959 1402 1719.34 2247 2289 
 
Prevalence (%)      
Active treatment 61.7 61.0 62.2 66.8 67.7 
Surgery  18.1 21.1 16.5 15.8 11.1 
RT 44.8 41.1 46.8 51.9 57.2 
  Brachy 20.5 13.4 14.7 22.2 26.9 
  IMRT 19.8 26.0 30.7 30.7 40.3 
  EBRT 12.5 10.0 11.0 8.7 9.2 
  SRS 0.3 0.1 0.3 0.3 0.5 
   Proton 0.5 0.9 0.6 1.7 0.2 
Biopsy 88.7 88.7 89.4 90.4 90.8 
Hormone  36.1 41.1 38.8 41.8 44.1 
Imaging  52.9 58.4 60.1 65.5 69.5 
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Table 10: Mean prostate treatment cost and prevalence of treatment according to HRR level total 
prostate cancer – related cost  (categorized in quintiles based on total prostate cancer-related cost)- 
Model 3 
 
1st quintile 
(Lowest) 2nd quintile 3rd quintile 4th quintile 
5th quintile 
(Highest) 
 
Cost ($)      
Total  12531 14097 14829 16023 17889 
Surgery 1761 2083 1575 1565 1435 
RT 8306 8780 9790 10494 12186 
Biopsy 1011 1025 1060 1095 1140 
Hormone 691 661 838 758 767 
Imaging 225 283 283 297 310 
Other 537 1265 1284 1814 2051 
 
Prevalence (%)      
Active treatment 64.7 61.7 63.1 65.4 64.3 
Surgery  18.2 19.6 15.8 15.8 13.9 
RT 47.8 43.4 48.1 50.3 51.3 
  Brachy 21.8 14.1 17.7 19.2 24.3 
  IMRT 22.7 28.2 29.1 31.0 35.6 
  EBRT 12.9 10.1 10.8 9.7 7.8 
  SRS 0.2 0.3 0.4 0.4 0.4 
Biopsy 89.4 90.7 89.5 90.2 88.5 
Hormone  38.1 37.2 43.5 40.7 42.2 
Imaging  56.7 59.6 61.1 63.8 64.7 
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Table 11: Mean prostate treatment cost and prevalence of treatment according to HRR level total 
prostate cancer – related cost  (categorized in quintiles based on total prostate cancer-related cost)- 
Model 4 
 
1st quintile 
(Lowest) 2nd quintile 3rd quintile 4th quintile 
5th quintile 
(Highest) 
 
Cost ($)      
Total  12370 13870 14780 15691 17773 
Surgery 1618 1621 1570 1646 1567 
RT 8304 9078 10132 10589 11915 
Biopsy 995 1072 1011 1047 1101 
Hormone 333 336 328 362 310 
Imaging 261 298 289 2756 292 
Other 861 1465 1449 1771 2588 
 
Prevalence (%)      
Active treatment 63.7 65.2 63.9 62.8 63.7 
Surgery  16.1 12.8 19.9 16.2 17.8 
RT 48.7 53.3 45.2 47.5 46.9 
  Brachy 20.2 20.9 17.3 18.3 21.3 
  IMRT 25.0 31.8 28.5 30.3 31.2 
  EBRT 14.1 11.5 7.7 10.9 7.3 
  SRS 0.2 0.4 0.5 0.3 0.3 
   Proton 0.3 0.3 0.8 0.5 1.9 
Biopsy 90.3 90.4 89.4 89.8 88.1 
Hormone  38.9 44.8 39.4 41.5 37.6 
Imaging  59.3 64.7 60.0 60.0 62.1 
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Appendix of Figures 
 
Figure 1. Years of life lost due to disability for different types of cancer (per 100,000) [13] 
 
Figure 2. Years of life lost due to disability for different types of cancer (per 100,000) [13] 
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Figure 3.  Cost Distribution (in euros) for all stages of prostate cancer by country [21] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 4: Selection of Cases 
 
 
 
 
 
 
114,914 patients 67 +years of age and with known diagnosis month
113,325 patients not reported from autopsy or death certificate only
72,879 without HMO and fully covered by Part A & B during 
70,976 without previous cancer from Medicare Claims
69,006 without a second cancer within 12 after prostate cancer
68446 with known HRR (more than 10 pts per HRR)
75 without known HRR, 485 from HRRs less than 10 
patients
1,803 had another cancer within 12 months
167 aged 95+
1,930 pts with previous cancer according to Medicare 
claims
40,446 pts had HMO or not fully covered by Part A 
& B during -24 -
1,589 reported from autopsy or death certificate 
only
60,417 pts <67 yrs at dx, 1016 without known 
month of dx
34 non-malignant pts, 4392 secondary pts, 693 
non-adenocarconima
46
182,467 diagnosed in 2003-7
176,347 adenocarcinoma
-24 - 12 months
70,809 aged 67-94
12 months
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    Figure 5. Mean Prostate Cancer related costs across HRRs 
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Figure 6a and 6b:  Mean prostate treatment cost and prevalence of treatment according to 
HRR level total prostate cancer – related cost  (Model 0) 
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Figure 7a and 7b:  Mean prostate treatment cost and prevalence of treatment according to 
HRR level total prostate cancer – related cost  (Model 1) 
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Figure 8a and 8b:  Mean prostate treatment cost and prevalence of treatment according to HRR 
level total prostate cancer – related cost  (Model 2) 
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Figure 9a and 9b:  Mean prostate treatment cost and prevalence of treatment according to HRR 
level total prostate cancer – related cost  (Model 3) 
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Figure 10a and 10b:  Mean prostate treatment cost and prevalence of treatment according to HRR 
level total prostate cancer – related cost  (Model 4) 
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